ArticleOncotarget2017
Downregulation of microRNA-31 inhibits proliferation and induces apoptosis by targeting
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- Higher expression of mir-31-5p is associated with reduced risk of head and neck keloid recurrence following surgical resection.Laryngoscope investigative otolaryngology · 2024Article
- Nanocarrier-Mediated Delivery of MicroRNAs for Fibrotic Diseases.Molecular diagnosis & therapy · 2024Review
- Hypoxia macrophage-derived exosomal miR-26b-5p targeting PTEN promotes the development of keloids.Burns & trauma · 2024Article
- Characterization of the skin keloid microenvironment.Cell communication and signaling : CCS · 2023Review
- Mechanisms underlying pathological scarring by fibroblasts during wound healing.International wound journal · 2023Article
- Multimodal roles of transient receptor potential channel activation in inducing pathological tissue scarification.Frontiers in immunology · 2023Review
- Advances in the pathogenesis and clinical application prospects of tumor biomolecules in keloid.Burns & trauma · 2022Review
- The Emerging Therapeutic Targets for Scar Management: Genetic and Epigenetic Landscapes.Skin pharmacology and physiology · 2022Review
- Epigenetic modification mechanisms involved in keloid: current status and prospect.Clinical epigenetics · 2020Review
- The integrative regulatory network of circRNA and microRNA in keloid scarring.Molecular biology reports · 2020Article
- Molecular determinants of mesenchymal cell activation in fibroproliferative diseases.Cellular and molecular life sciences : CMLS · 2019Review
- Integrated Interaction Network of MicroRNA Target Genes in Keloid Scarring.Molecular diagnosis & therapy · 2019Article
- MiR‑500a‑5p promotes glioblastoma cell proliferation, migration and invasion by targeting chromodomain helicase DNA binding protein 5.Molecular medicine reports · 2018Article
- Downregulation of miR‑637 promotes proliferation and metastasis by targeting Smad3 in keloids.Molecular medicine reports · 2018Article
- Recent Understandings of Biology, Prophylaxis and Treatment Strategies for Hypertrophic Scars and Keloids.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
microRNAs (miRNAs) play a pivotal role in the regulation of cell proliferation and apoptosis in keloid scarring. Integrative analysis of the previous miRNA microarray revealed miRNA-31 was among the most frequently altered miRNAs in keloid and hypertrophic scar. Using qRT-PCR, we further validated miRNA-31 was increased in keloid tissues and keloid-derived fibroblasts. Moreover, downregulation of miRNA-31 inhibited the cell proliferation, induced the cell apoptosis and disturbed the cell cycle progression by targeting
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.